

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>ARCH Venture Partners XII, LLC</u> (Last) (First) (Middle) 8755 W. HIGGINS ROAD, SUITE 1025 (Street) CHICAGO IL 60631 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Rapport Therapeutics, Inc. [RAPP]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 06/10/2024	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Rule 10b5-1(c) Transaction Indication

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/10/2024		C ⁽¹⁾		3,728,738	A	\$0.00	3,728,738	I	By ARCH Venture Fund XII, L.P. ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	(1)	06/10/2024		C ⁽¹⁾		20,000,000		(1)	(1)	Common Stock	2,336,000	\$0.00	0	I	By ARCH Venture Fund XII, L.P. ⁽²⁾
Series B Preferred Stock	(1)	06/10/2024		C ⁽¹⁾		11,924,138		(1)	(1)	Common Stock	1,392,738	\$0.00	0	I	By ARCH Venture Fund XII, L.P. ⁽²⁾

1. Name and Address of Reporting Person*
ARCH Venture Partners XII, LLC
 (Last) (First) (Middle)
 8755 W. HIGGINS ROAD, SUITE 1025
 (Street)
 CHICAGO IL 60631
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
ARCH Venture Partners XII, L.P.
 (Last) (First) (Middle)
 8755 W. HIGGINS ROAD, SUITE 1025
 (Street)
 CHICAGO IL 60631
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
ARCH Venture Fund XII, L.P.
 (Last) (First) (Middle)
 8755 W. HIGGINS ROAD, SUITE 1025

(Street)	CHICAGO	IL	60631
(City)	(State)	(Zip)	
1. Name and Address of Reporting Person*			
CRANDELL KEITH			
(Last)	(First)	(Middle)	
8755 W. HIGGINS ROAD, SUITE 1025			
(Street)	CHICAGO	IL	60631
(City)	(State)	(Zip)	
1. Name and Address of Reporting Person*			
NELSEN ROBERT			
(Last)	(First)	(Middle)	
8755 W. HIGGINS ROAD, SUITE 1025			
(Street)	CHICAGO	IL	60631
(City)	(State)	(Zip)	
1. Name and Address of Reporting Person*			
Burow Kristina			
(Last)	(First)	(Middle)	
8755 W. HIGGINS ROAD, SUITE 1025			
(Street)	CHICAGO	IL	60631
(City)	(State)	(Zip)	
1. Name and Address of Reporting Person*			
GILLIS STEVEN			
(Last)	(First)	(Middle)	
8755 W. HIGGINS ROAD, SUITE 1025			
(Street)	CHICAGO	IL	60631
(City)	(State)	(Zip)	

Explanation of Responses:

1. Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date.

2. Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

[ARCH Venture Fund XII, L.P.](#)
 By: [ARCH Venture Partners XII, L.P.](#), its General Partner By: [ARCH Venture Partners XII, LLC](#), its General Partner By: [/s/ Mark McDonnell, as Attorney-in-Fact](#) [06/10/2024](#)

[ARCH Venture Partners XII, L.P.](#) By: [ARCH Venture Partners XII, LLC](#), its General Partner By: [/s/ Mark McDonnell, as Attorney-in-Fact](#) [06/10/2024](#)

[ARCH Venture Partners XII, LLC](#) By: [/s/ Mark McDonnell, as Attorney-in-Fact](#) [06/10/2024](#)

[/s/ Keith Crandell, By: Mark McDonnell, attorney-in-fact](#) [06/10/2024](#)

[/s/ Kristina Burow, By: Mark McDonnell, attorney-in-fact](#) [06/10/2024](#)

[/s/ Steven Gillis, By: Mark McDonnell, attorney-in-fact](#) [06/10/2024](#)

[/s/ Robert Nelsen, By: Mark](#) [06/10/2024](#)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.